Stonebridge Capital Advisors LLC Sells 1,180 Shares of Express Scripts Holding Company (ESRX)
Stonebridge Capital Advisors LLC cut its holdings in shares of Express Scripts Holding Company (NASDAQ:ESRX) by 4.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,879 shares of the company’s stock after selling 1,180 shares during the quarter. Stonebridge Capital Advisors LLC’s holdings in Express Scripts were worth $1,449,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Burt Wealth Advisors increased its position in shares of Express Scripts by 11.4% during the second quarter. Burt Wealth Advisors now owns 1,696 shares of the company’s stock valued at $108,000 after buying an additional 174 shares during the period. CKW Financial Group increased its position in shares of Express Scripts by 20.0% during the second quarter. CKW Financial Group now owns 1,800 shares of the company’s stock valued at $115,000 after buying an additional 300 shares during the period. Bank of Nova Scotia Trust Co. bought a new stake in shares of Express Scripts during the third quarter valued at about $120,000. First Personal Financial Services increased its position in shares of Express Scripts by 199.1% during the second quarter. First Personal Financial Services now owns 2,103 shares of the company’s stock valued at $134,000 after buying an additional 1,400 shares during the period. Finally, Financial Management Professionals Inc. increased its position in shares of Express Scripts by 140.1% during the second quarter. Financial Management Professionals Inc. now owns 2,334 shares of the company’s stock valued at $149,000 after buying an additional 1,362 shares during the period. Hedge funds and other institutional investors own 88.44% of the company’s stock.
In other Express Scripts news, VP Phyllis S. Anderson sold 643 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $62.37, for a total transaction of $40,103.91. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Timothy C. Wentworth purchased 8,000 shares of Express Scripts stock in a transaction on Tuesday, October 31st. The shares were acquired at an average price of $61.13 per share, for a total transaction of $489,040.00. Following the completion of the transaction, the chief executive officer now directly owns 98,628 shares of the company’s stock, valued at $6,029,129.64. The disclosure for this purchase can be found here. 0.68% of the stock is owned by company insiders.
Express Scripts (NASDAQ:ESRX) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.90 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.90. The company had revenue of $24.68 billion for the quarter, compared to analysts’ expectations of $25.68 billion. Express Scripts had a net margin of 3.64% and a return on equity of 25.46%. Express Scripts’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same period in the prior year, the business earned $1.74 earnings per share. analysts anticipate that Express Scripts Holding Company will post 7.01 EPS for the current year.
Several equities research analysts have recently weighed in on ESRX shares. Jefferies Group set a $72.00 price target on Express Scripts and gave the company a “buy” rating in a research report on Tuesday, August 29th. Robert W. Baird reiterated a “hold” rating and set a $56.00 price target on shares of Express Scripts in a research report on Friday, September 1st. ValuEngine cut Express Scripts from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Royal Bank of Canada started coverage on Express Scripts in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $68.00 price target on the stock. Finally, UBS cut Express Scripts from a “market perform” rating to an “underperform” rating in a research report on Monday, October 9th. Six analysts have rated the stock with a sell rating, eleven have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $70.67.
Express Scripts Company Profile
Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).
Receive News & Stock Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related stocks with our FREE daily email newsletter.